Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Non-Hodgkin's Lymphoma and Multiple Myeloma
Last updated January 6, 2014
Apprilon (doxycycline monohydrate)
Status:
Negotiations were not pursued
Manufacturer:
Galderma Canada Inc.
Indication:
Rosacea
Last updated December 17, 2013
Votrient (pazopanib hydrochloride)
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Metastatic Renal Cell Carcinoma
Last updated December 2, 2013
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Metastatic Renal Cell Carcinoma
Last updated November 22, 2013
Status:
Concluded with an LOI
Manufacturer:
Optimer Pharmaceuticals
Indication:
Clostridium difficile infection
Last updated November 13, 2013
Edarbyclor (azilsartan medoxomil/chlorthalidone)
Status:
Negotiations were not pursued
Manufacturer:
Takeda Canada Inc.
Indication:
Hypertension
Last updated November 12, 2013
Status:
Negotiations were not pursued
Manufacturer:
Takeda Canada Inc.
Indication:
Hypertension
Last updated November 12, 2013
Status:
Negotiations were not pursued
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex (TSC)
Last updated November 1, 2013
Status:
Negotiations were not pursued
Manufacturer:
Valeant Canada
Indication:
Insomnia, short-term treatment
Last updated October 24, 2013
Perjeta/Herceptin (pertuzumab/trastuzumab)
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Metastatic Breast Cancer
Last updated October 18, 2013